In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

Glioblastoma (GBM), a highly lethal brain cancer, is notorious for immunosuppression, but
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …

Background: Rupture and erosion of advanced atherosclerotic lesions with a resultant
myocardial infarction or stroke are the leading worldwide cause of death. However, we have …

Despite the impressive impact of CTLA 4 and PD 1‐PDL 1‐targeted cancer immunotherapy,
a large proportion of patients with many tumor types fail to respond. Consequently, the focus …

Galectin-3 is a member of the galectin family, which are β‑galactoside‑binding lectins with≥
1 evolutionary conserved carbohydrate‑recognition domain. It binds proteins in a …

Cancer immunotherapy and tumor microenvironment have been at the forefront of research
over the past decades. Targeting immune checkpoints especially programmed death 1 (PD …

Decades of research have disclosed a plethora of alterations in protein glycosylation that
decisively impact in all stages of disease and ultimately contribute to more aggressive cell …

Galectin-3 (Gal-3) regulates basic cellular functions such as cell–cell and cell–matrix
interactions, growth, proliferation, differentiation, and inflammation. It is not surprising …

Immune checkpoint therapy has revolutionized cancer treatment by blocking inhibitory
pathways in T cells that limits the an effective anti-tumor immune response. Therapeutics …